Abdominal Neoplasms
📧 Sign up to get email alerts when something new happens for Abdominal Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-04EMA Authorised: Vitrakvi (larotrectinib sulfate) — Bayer AG
EMA authorised Vitrakvi (larotrectinib sulfate) for use in abdominal neoplasms under conditional approval.
-
EMA approval · 2026-07-22EMA Authorised: Vitrakvi (larotrectinib sulfate) — Bayer AG
The EMA authorises Vitrakvi (larotrectinib sulfate) from Bayer AG with conditional approval for abdominal neoplasms.
-
EMA approval · 2026-07-14EMA Authorised: Vitrakvi (larotrectinib sulfate) — Bayer AG
EMA has authorised Vitrakvi (larotrectinib sulfate) by Bayer AG with conditional approval for abdominal neoplasms.
-
EMA approval · 2026-03-11EMA Authorised: Vitrakvi (larotrectinib sulfate) — Bayer AG
EMA authorised Vitrakvi (larotrectinib sulfate) for abdominal neoplasms with conditional approval; Bayer AG is the marketing authorisation h…